Which hedge funds own CBIO? CRESCENT BIOPHARMA INC., Q2 2026 13F holders
5 of the hedge funds tracked by WhaleCreep disclosed a position in CBIO (CRESCENT BIOPHARMA INC.) in their Q2 2026 13F filings, worth $18.7m in total. The largest holder by portfolio weight is Moore Capital Management at 0.0% of its book. 2 exited: Brevan Howard Capital Management, Renaissance Technologies LLC.
5tracked managers holding
0opened this quarter
2exited this quarter
Which hedge funds hold CBIO? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Moore Capital Management | Q2 2026 | 0.0% | $450.0k | 25,000 | 0% | held |
| Point72 Asset Management LP | Q2 2026 | 0.0% | $5.4m | 300,000 | 0% | held |
| Woodline Partners | Q2 2026 | 0.0% | $1.7m | 94,488 | 28% | added |
| Millennium Management | Q2 2026 | 0.0% | $7.3m | 403,859 | 25% | added |
| Marshall Wace | Q2 2026 | 0.0% | $3.9m | 214,300 | 7% | added |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Brevan Howard Capital Management | 0.0% | $358.8k |
| Renaissance Technologies LLC | 0.0% | $445.7k |
How has hedge fund ownership of CBIO changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 5 | $18.7m |
| Q1 2026 | 7 | $17.8m |
| Q4 2025 | 4 | $5.3m |
| Q3 2025 | 1 | $319.8k |
Counts every tracked manager that disclosed CBIO in that quarter's filing, including managers that have since stopped filing.